| USFDA nod for Simvastatin by Indian firms |
| Our Web Bureau / Mumbai December 21, 2006 |
| Ranbaxy Pharmaceuticals Inc. (RPI), a wholly-owned subsidiary of Ranbaxy Labs, has received US Food and Drug Administration (FDA) approval to manufacture and market Simvastatin USP in 5 mg, 10mg, 20mg and 40mg tablet form in the US. According to an official release issued by Ranbaxy to the BSE today, the FDA office of generic drugs has determined that Ranbaxy |
